

## Dissecting the host response to a $\gamma$ -herpesvirus

Peter C. Doherty, Jan P. Christensen, Gabrielle T. Belz, Philip G. Stevenson and Mark Y. Sangster

*Phil. Trans. R. Soc. Lond. B* 2001 **356**, 581-593

doi: 10.1098/rstb.2000.0786

---

### References

#### Article cited in:

<http://rstb.royalsocietypublishing.org/content/356/1408/581#related-urls>

### Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right-hand corner of the article or click [here](#)

---

To subscribe to *Phil. Trans. R. Soc. Lond. B* go to: <http://rstb.royalsocietypublishing.org/subscriptions>

---

# Dissecting the host response to a $\gamma$ -herpesvirus

Peter C. Doherty<sup>1\*</sup>, Jan P. Christensen<sup>2</sup>, Gabrielle T. Belz<sup>3</sup>, Philip G. Stevenson<sup>4</sup>  
and Mark Y. Sangster<sup>1</sup>

<sup>1</sup>*Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA*

<sup>2</sup>*Institute of Medical Microbiology and Immunology, University of Copenhagen, Copenhagen, DK 2200 N, Denmark*

<sup>3</sup>*The Walter and Eliza Hall Institute for Medical Research, Parkville 3050, Australia*

<sup>4</sup>*Division of Virology, University of Cambridge, Cambridge CB2 2QQ, UK*

The murine  $\gamma$ -herpesvirus 68 (MHV-68) provides a unique experimental model for dissecting immunity to large DNA viruses that persist in B lymphocytes. The analysis is greatly facilitated by the availability of genetically disrupted ( $-/-$ ) mice that lack key host-response elements, and by the fact that MHV-68 is a lytic virus that can readily be manipulated for mutational analysis. The mutant virus strategy is being used, for example, to characterize the part played *in vivo* by an MHV-68-encoded chemokine-binding protein that may ultimately find an application in human therapeutics. Experiments with various  $-/-$  mice and monoclonal antibody depletion protocols have shown very clearly that type I interferons (IFNs) are essential for the early control of MHV-68 replication, while CD4<sup>+</sup> T cells producing IFN- $\gamma$  function to limit the consequences of viral persistence. Virus-specific CD8<sup>+</sup> effectors acting in the absence of the CD4<sup>+</sup> subset seem initially to control the lytic phase in the lung following respiratory challenge, but are then unable to prevent the reactivation of replicative infection in epithelia and the eventual death of CD4<sup>+</sup> T-cell-deficient mice. This could reflect the fact that the interaction between the CD8<sup>+</sup> T cells and the virus-infected targets is partially compromised by the MHV-68 K3 protein, which inhibits antigen presentation by MHC class I glycoproteins. Immunization strategies focusing on the CD8<sup>+</sup> T-cell response to epitopes expressed during the lytic phase of MHV-68 infection can limit virus replication, but are unable to prevent the establishment of latency. Other experiments with mutant viruses also suggest that there is a disconnection between lytic MHV-68 infection and latency. The massive non-specific immunoglobulin response and the dramatic expansion of V $\beta$ 4<sup>+</sup> CD8<sup>+</sup> T cells, which is apparently MHC independent, could represent some sort of 'smoke screen' used by MHV-68 to subvert immunity. Although MHV-68 is neither Epstein-Barr virus nor human herpesvirus-8, the results generated from this system suggest possibilities that may usefully be addressed with these human pathogens. Perhaps the main lesson learned to date is that all the components of immunity are likely to be important for the control of these complex viruses.

**Keywords:** vaccination; cell-mediated immunity; immunodeficiency; autoimmunity; chemokines; homeostasis

## 1. INTRODUCTION

The rhadinoviruses or  $\gamma_2$ -herpesviruses include a spectrum of related pathogens known to infect voles (Blaskovic *et al.* 1980; Efstathiou *et al.* 1990), mice (MHV-68), horses, pigs, a number of free-living and domestic ruminants and a variety of primates (Gompels *et al.* 1988; Greensill *et al.* 2000; Li *et al.* 2000*a,b*; Ensser *et al.* 1997; Ehlers *et al.* 1999; Holloway *et al.* 1999; Alexander *et al.* 2000). Some of these viruses have also been transmitted experimentally to hamsters, rats, rabbits and guinea-pigs (Jacoby *et al.* 1988). By contrast the lymphocryptoviruses or  $\gamma_1$ -herpesviruses have, to date, been found only in primates. Most attention is, for obvious reasons, focused on the two prototype  $\gamma_1$ - and  $\gamma_2$ -herpesviruses that infect humans, Epstein-Barr virus (EBV) and human herpes-

virus 8 (HHV-8) (Rickinson & Keiff 1996; Chang *et al.* 2000, respectively). In addition, the  $\gamma_2$ -herpesviruses that cause malignant catarrhal fevers in ruminants can constitute substantial problems for wildlife, zoo populations and animal agriculture (Gulland *et al.* 1989; Reid & Rowe 1973).

Two practical questions come to mind when we consider immunity to the  $\gamma$ -herpesviruses. The first is whether it is possible to make effective vaccines against this class of pathogens, a possibility that has received some attention for EBV in cotton-top tamarins and humans (Epstein 1986; Morgan *et al.* 1988; Thomson *et al.* 1996, 1998; Wilson *et al.* 1999). The second addresses the much more speculative idea that appropriately engineered  $\gamma$ -herpesviruses might be used as vaccine-delivery vehicles. Although it may well be true that antigen persistence is not essential for maintaining (at least) CD8<sup>+</sup> T-cell memory (Murali-Krishna *et al.* 1999), it is likely that

\*Author for correspondence (peter.doherty@stjude.org).

regular boosting enhances the quality of such memory (Christensen *et al.* 2000). Can we make safe  $\gamma$ -herpesvirus mutants that persist and regularly reactivate from latency? Could such a variant that carries, for example, immunogenic peptides derived from the human immunodeficiency virus (HIV) function as a permanent, self-boosting immunogen? Obviously, the testing of such a live vaccine would need to be very stringent.

The MHV-68 model offers a unique experimental system (Nash & Sunil-Chandra 1994; Simas & Efstathiou 1998; Virgin & Speck 1999; Speck & Virgin 1999), both for dissecting the basis of immunity and for the development of vaccine strategies at the level of 'proof of principle'. Unlike EBV and HHV-8, MHV-68 causes rapid, lytic infection in a spectrum of cell lines and primary cultures. This means that it is relatively easy to generate deletion mutants, a strategy that has been pursued with great effectiveness over the past three years. The fact that MHV-68 is so lytic may explain why it is much less likely to cause transformation than either EBV or HHV-8. A cell line persistently infected with MHV-68 has been isolated from murine lymphoma (Sunil-Chandra *et al.* 1994), but the virus does not 'immortalize' lymphocytes in culture, although it carries (Van Dyk *et al.* 1999) at least one potential oncogene (a cyclin D homologue). Even so, the fact that MHV-68 establishes latency in B lymphocytes (Sunil-Chandra *et al.* 1992) and macrophages (Pollock *et al.* 1997) *in vivo* means that the effectiveness of any vaccine strategy for controlling both the replicative and persistent phases of  $\gamma$ -herpesvirus infections can readily be evaluated.

The capacity to do *in vivo* experiments, together with the spectrum of reagents that are unique to the laboratory mouse, has allowed the rapid dissection of immunity to MHV-68 (Nash & Sunil-Chandra 1994; Virgin & Speck 1999). Even so, although progress to date has been considerable, there is much to be done and new experiments (especially with mutant viruses) continue to open out novel possibilities. We now know that both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell effectors play major roles in the control of MHV-68 infection (Ehtisham *et al.* 1993; Christensen *et al.* 1999). Kinetic studies have characterized the CD4<sup>+</sup> T-cell, CD8<sup>+</sup> T-cell, B-cell and antibody responses through the initial phase of replicative infection into long-term memory (Christensen & Doherty 1999; Stevenson *et al.* 1999a,b; Sangster *et al.* 2000), if 'memory' is a term that can be used legitimately when discussing a persistent virus. A few vaccine strategies have been tried (Stewart *et al.* 1999; Belz *et al.* 2000; Stevenson *et al.* 1999b; Liu *et al.* 1999b), although we still know relatively little about antigen specificity in (particularly) the CD4<sup>+</sup> T- and B-cell compartments. The aim of this review is both to summarize what we have learned to date about the host response to MHV-68, and to persuade others interested in the  $\gamma$ -herpesviruses that it is worth thinking about the findings generated in this readily manipulated model system.

## 2. PATHOGENESIS OF MHV-68 INFECTION

Several modes of virus challenge have been used to analyse the disease process caused by MHV-68. The group of Nash, Efstathiou and colleagues (University of

Cambridge, UK) used intranasal (i.n.) challenge of anaesthetized mice when they initiated both the molecular and immunological dissection of MHV-68 pathogenesis (Nash & Sunil-Chandra 1994). This protocol has been followed by most of those working directly on  $\gamma$ -herpesvirus-specific immunity (Cardin *et al.* 1996; Coppola *et al.* 1999; Lee *et al.* 2000). The approach favoured by Virgin and Speck (Washington University, St Louis, MI, USA) is to inject a large dose of MHV-68 intraperitoneally (i.p.) (Virgin & Speck 1999; Speck & Virgin 1999), a method that has merit for evaluating the pathogenesis of replication-defective mutant viruses. Oral exposure has also been shown to result in virus replication in the intestinal epithelium, establishing that MHV-68 can transit the acid environment of the stomach (Peacock & Bost 2000). The virus is probably transmitted in nature via the gastrointestinal or respiratory route but, although no contemporary comparison has been made, the longer-term profiles of persistence and latency are likely to be broadly comparable for these three modes of infection. Any mention of samples taken from the lung, cervical lymph node (CLN), mediastinal lymph node (MLN) or bronchoalveolar lavage (BAL) populations throughout this review obviously refers to mice that had been given MHV-68 by the i.n. route.

The virus first establishes itself as a productive infection of the respiratory epithelium. Within a few days, evidence of MHV-68 replication can also be detected in distal epithelial sites, including the adrenals. No evidence has been found for plasma viraemia, and it is thought that infected B cells are important for the blood-borne dissemination of this pathogen (Weck *et al.* 1996). In normal mice, the lytic phase is essentially controlled within 10–12 days, although evidence for low-level virus persistence in the lung can still be demonstrated in the long term by polymerase chain reaction (PCR) and *in situ* hybridization analysis (Stewart *et al.* 1998).

Latent infection of the B-lymphocyte compartment can also be detected soon after i.n. or i.p. challenge (Sunil-Chandra *et al.* 1992; Cardin *et al.* 1996). Somewhat surprisingly, the extent of latency seems relatively independent of virus seeding from the infected epithelium (Stevenson *et al.* 1999b; Clambey *et al.* 2000), supporting the idea of Thorley-Lawson (developed for EBV) that persistence is first established as a consequence of virus entry into naive B cells (Babcock *et al.* 1998). These latently infected B cells are then considered to assume a 'memory' phenotype, and are regulated by the same homeostatic processes that control long-term B-cell memory (Thorley-Lawson *et al.* 1996). Studies of  $\mu$ MT mice that have a disrupted immunoglobulin (Ig)  $\mu$ -chain (Ig<sup>-/-</sup>), and thus lack B cells, established that MHV-68 can also persist in macrophages (Weck *et al.* 1996). This was missed when the extent of latency was measured by a classical infectious-centre assay (Usherwood *et al.* 1996b), but can be demonstrated by a more sensitive limiting-dilution analysis (LDA) and, of course, by appropriate PCR protocols (Weck *et al.* 1996).

The overall impression is thus that the pathogenesis of both the acute and persistent phases of EBV and MHV-68 infection share many features, although the molecular differences between these two viruses are such that each will obviously have unique features. Little is known about

the early phases of HHV-8 infection, so it is not clear how closely the MHV-68 mouse model mimics this disease process. We shall no doubt understand the likely pathogenesis of HHV-8 infection better as the issue is pursued with other  $\gamma_2$ -herpesviruses in non-human primates (Greensill *et al.* 2000). Hopefully the findings from the cheap, and readily manipulated, MHV-68 model will have some influence on the design of those experiments.

### 3. THE CD8<sup>+</sup> T-CELL RESPONSE

Prior to the development of the MHV-68 mouse model, everything that was known about the nature of cell-mediated immunity (CMI) to the  $\gamma$ -herpesviruses was derived from studies of EBV infection in normal and immunologically compromised individuals (Rickinson & Moss 1997). This extraordinarily effective research effort on the part of a relatively small group of investigators has led to an understanding of CD8<sup>+</sup> T-cell specificity profiles that is unparalleled for any other virus disease of humans. Both the cost and the absence of a convenient, well-characterized experimental system have, however, inhibited *in vivo* analysis of the functional significance of EBV-specific CD8<sup>+</sup> T-cell-mediated immunity. Those working with HIV have been somewhat more fortunate in this regard. The availability of the simian immunodeficiency virus model, together with the enormous financial resources that have been dedicated to this problem, is leading to rapid clarification of the strengths and limitations of the CD8<sup>+</sup> T-cell response to primate lentiviruses (Egan *et al.* 2000; Kuroda *et al.* 1999). Our understanding of CD8<sup>+</sup> T-cell function with the  $\gamma$ -herpesviruses has been greatly enhanced by recent experiments with MHV-68. Would the analysis of immunity to the HIVs have moved much more rapidly if there had been a naturally occurring mouse lentivirus?

#### (a) *Measuring the MHV-68-specific CD8<sup>+</sup> T-cell response*

One property that MHV-68 shares with HHV-8 is that the homologous K3 genes of these two viruses can function to reduce the level of cell-surface expression for MHC class I glycoproteins (Stevenson *et al.* 2000; Ishido *et al.* 2000). The HHV-8 K3 gene product has been shown to target class I MHC molecules for rapid degradation in lysosomal vesicles (Coscoy & Ganem 2000). This may explain why the demonstration of MHV-68-specific cytotoxic T-lymphocyte (CTL) activity initially proved to be difficult. The problem was, however, overcome and kinetic analysis of the virus-specific CD8<sup>+</sup> T-cell response in BALB/c (H-2<sup>d</sup>) mice that were challenged *i.n.* with MHV-68 showed profiles (Stevenson & Doherty 1998) that were much like those that might have been expected from studies with other viruses (Doherty *et al.* 1992).

Evidence of MHV-68-specific CTL activity was found during the acute phase of the infectious process in the regional MLN and the spleen, then declined to background levels in the longer term (Stevenson & Doherty 1998). As with primary respiratory pathogens like influenza virus and Sendai virus (Doherty *et al.* 1997b), peak levels of effector function were detected in the inflamma-

tory cell population that was recovered by BAL of the infected lung. Again, both CD8<sup>+</sup> T-cell numbers and the level of MHV-68-specific CTL activity declined subsequent to the reduction of virus titres and as a consequence, antigen load. LDA of spleen and MLN populations extending for four months beyond virus challenge indicated that the frequency of MHV-68-specific 'memory' CTL precursors for this persistent virus was no higher than for influenza virus or Sendai virus (Doherty *et al.* 1996; Stevenson & Doherty 1998), negative-strand RNA viruses that are not known to be maintained in any form after the initial phase of infection.

The initial LDA and CTL studies thus left us with some understanding of the scope and duration of the CTL response, but with no information about the fine specificity of these CD8<sup>+</sup> T cells. This situation changed very quickly with the publication of the full sequence of MHV-68 (Virgin *et al.* 1997), allowing the identification of viral gene products that would probably be expressed in the lytic phase of the infectious process. This in turn facilitated the selection of peptides (Falk *et al.* 1991) that were likely to be bound by the H-2K<sup>b</sup> and H-2D<sup>b</sup> MHC class I glycoproteins of the H-2<sup>b</sup> haplotype in C57BL/6J (B6) mice (table 1). Two of these epitopes were identified by classical protocols using CTL effectors or hybridoma cell lines (Liu *et al.* 1999b; Stevenson *et al.* 1999a), while the majority were found by a new flow-cytometric approach that measures cytoplasmic interferon- $\gamma$  (IFN- $\gamma$ ) subsequent to *in vitro* stimulation with peptide (Pep $\gamma$  assay).

The Pep $\gamma$  assay is one of two analytical systems that have revolutionized our understanding of CD8<sup>+</sup> T-cell-mediated immunity over the past three years (McMichael & O'Callaghan 1998; Doherty 1998). Flow-cytometric analysis of acute lymphocytic choriomeningitis virus (LCMV) infection with fluorochrome-labelled, tetrameric complexes of MHC class I glycoprotein; peptide (tetramers) demonstrated unequivocally that the numbers of LCMV-specific CD8<sup>+</sup> T cells present during the acute and convalescent stages of this disease process were at least tenfold in excess of the values previously inferred from LDA experiments (Murali-Krishna *et al.* 1998). Comparable results were found for T-cell populations that were stimulated *in vitro* with peptide in the presence of brefeldin A (to stop protein secretion), then stained for cytoplasmic IFN- $\gamma$ . We quickly used the Pep $\gamma$  assay (Stevenson *et al.* 1999a) to measure the magnitude of the MHV-68-specific response (figure 1), while Altman at Emory University, Atlanta, GA, USA made tetrameric complexes (Altman *et al.* 1996) for the two most prominent MHV-68 peptides.

The MHV-68 peptides identified in table 1 account for more than 70% of the CD8<sup>+</sup> T cells detected in the BAL of acutely infected B6 mice (Stevenson *et al.* 1999a), suggesting that the experiments are measuring the great majority of the CD8<sup>+</sup> T-cell response to lytic phase epitopes. Extensive screening of overlapping 'mimotopes' with the Pep $\gamma$  assay has not led to the detection of other peptides (table 1) presented during the acute phase of MHV-68 infection in H-2<sup>b</sup> mice. Also, despite intensive effort, no evidence has been found for epitopes that might be presented by H-2K<sup>b</sup> or H-2D<sup>b</sup> during latency. This search for a latency-associated CMI response has been a

Table 1. *The MHV-68 peptides recognized by CD8<sup>+</sup> T cells in H-2<sup>b</sup> mice*

(The 'p' refers to the pin number in the original mimeotope screen. Most of these peptides were originally described by Stevenson *et al.* (1999a) and Liu *et al.* (1999a).)

identifier	MHC restriction	amino-acid sequence	gene/amino-acid number	putative protein homology
p56	D <sup>b</sup>	AGPHNDMEI	ORF 6 <sub>487-495</sub>	ssDNA-binding protein
p79	K <sup>b</sup>	TSINLVKI	ORF 61 <sub>524-531</sub>	ribonuclease reductase large
p11	not tested	DCTQFTKL	ORF 9 <sub>395-402</sub>	DNA polymerase
p77	not tested	PYILNKKAI	ORF 61 <sub>370-378</sub>	ribonuclease reductase large
p119	not tested	IKYVYNFL	ORF 44 <sub>438-490</sub>	helicase primase
p214	not tested	IVCVNFEKI	ORF 11 <sub>131-139</sub>	unknown
gB	K <sup>b</sup>	KNYIFEEKL	ORF 8-gB <sub>604-612</sub>	glycoprotein B

little more successful with H-2<sup>d</sup> mice (Husain *et al.* 1999; Usherwood *et al.* 2000), where CD8<sup>+</sup> T cells specific for an H-2K<sup>d</sup>-restricted peptide derived from the viral M2 gene product have been shown to modulate the initial load of infected B cells, although there was no effect on numbers in the long term. This latency-associated epitope may, it seems, be expressed for only a relatively short interval.

Kinetic analysis of the CD8<sup>+</sup> T-cell response to MHV-68 showed the general profile established previously for other respiratory virus infections (Stevenson *et al.* 1998, 1999a; Doherty & Christensen 2000). The numbers of CD8<sup>+</sup> T cells specific for the p56, p79 and p11 peptides in B6 mice increase rapidly from about day 10 after i.n. challenge (figure 1a–d), then decline after termination of the lytic phase of the infection. The MHV-68-specific CD8<sup>+</sup> set concentrates in the BAL population recovered from the site of virus-induced pathology in the lung, with three peptides (p56, p79 and p11) accounting for most of the CD8<sup>+</sup> T cells that localize to the respiratory tract at the time that the virus is being controlled (figure 1a). The response to D<sup>b</sup>-restricted p56 peptide peaks a little earlier, while the K<sup>b</sup>-restricted p59-specific population remains at higher prevalence for longer (figure 1a–d). Probing stimulator cell populations from the MLN and spleen with a T-cell hybridoma assay has shown that the difference in CD8<sup>+</sup> T-cell response profiles for these two epitopes reflects distinct phases of antigen presentation in the lymphoid tissue (Liu *et al.* 1999a). Also, dendritic cells, macrophages and B cells isolated directly from infected mice were all found to be presenting MHV-68 peptides. Other, biological evidence suggests that B cells are particularly important for the p79-specific response (Stevenson *et al.* 1998, 1999a).

#### (b) *Extent of CD8<sup>+</sup> T-cell-mediated control*

Early experiments completed prior to the development of a capacity for measuring either CTL activity or virus-specific T-cell numbers indicated that the replicative phase of MHV-68 infection is dealt with very effectively by virus-specific CD8<sup>+</sup> effectors (Ehtisham *et al.* 1993). Mice (BALB/c, H-2<sup>d</sup>) that were depleted of the CD4<sup>+</sup> T-cell subset by treatment with an appropriate monoclonal antibody (mAb) reduced virus titres in the lung, and seemed to be recovering when the experiment was terminated by three weeks after virus challenge. The same result was found for the acute phase of MHV-68 infection in B6 mice that lack CD4<sup>+</sup> T cells due to homozygous disruption of the H2IA<sup>b</sup> MHC class II gene (II<sup>-/-</sup>). This

apparent CD8<sup>+</sup> T-cell-mediated control of productive MHV-68 infection in the MHC II<sup>-/-</sup> mice proved, however, to be transient (Cardin *et al.* 1996). The lytic phase in the lung soon re-emerged, although virus production stabilized at titres that were generally at least 100 times lower than those detected prior to the onset of immunity. Even so, the MHC II<sup>-/-</sup> group developed a uniformly lethal wasting syndrome after 90–120 days. The CD8<sup>+</sup> T-cell response acting alone can thus limit MHV-68 infection, but is ultimately unable to protect against the development of fatal disease.

The initial interpretation of these results was that, as argued for persistent LCMV infection, there was a requirement for CD4<sup>+</sup> T-cell help to promote the CD8<sup>+</sup> T-cell response (Christensen *et al.* 1994). However, when we looked closely at the long-term prevalence of MHV-68-specific CD8<sup>+</sup> T cells in the MHC II<sup>-/-</sup> mice (Grusby *et al.* 1991), we found that they were generally present at higher frequency than in the conventional, MHC II<sup>+/+</sup> B6 controls, reflecting the greater antigen load resulting from virus reactivation to lytic phase (Stevenson *et al.* 1998). Furthermore, unlike the situation for the mice with persistent LCMV infection (Zajac *et al.* 1998), the MHV-68-specific CD8<sup>+</sup> effectors produced IFN- $\gamma$  when pulsed with the viral p56 or p79 peptides (Stevenson *et al.* 1998). Thus, at least by the criterion of IFN- $\gamma$  production following *in vitro* exposure to a large dose of peptide, they did not seem to be functionally defective. We are currently looking more closely to see if we can find evidence of some other impairment in these T cells.

#### (c) *Expansion of a V $\beta$ 4<sup>+</sup> CD8<sup>+</sup> population: infectious mononucleosis in the mouse?*

A characteristic of MHV-68 infection is the massive expansion of a diverse CD8<sup>+</sup> T-cell population expressing the V $\beta$ 4 T-cell receptor (TCR) chain in conjunction with a variety of TCR- $\alpha$  chains (Tripp *et al.* 1997; Hardy *et al.* 2000). Greatly increased numbers of these lymphocytes are first observed subsequent to the resolution of the acute phase of the infectious process, and persist for a month or more. The continued presence of this large, activated (CD62L<sup>lo</sup>) CD8<sup>+</sup> T-cell population in both the peripheral blood and lymphoid tissue suggested initially that the V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell expansion might be comparable with the infectious mononucleosis (IM) syndrome detected (particularly) in adolescents suffering primary EBV infection (Henle *et al.* 1968).




Figure 1. The CD8<sup>+</sup> T-cell response. Quantification of the peptide-specific CD8<sup>+</sup> T-cell response by intracellular IFN- $\gamma$  staining (*a-d*) and comparison with V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell numbers (*e,f*) following i.n. infection with 600 plaque-forming units of MHV-68. Cells were pooled from six mice per time-point, and incubated for 6 h in the presence of brefeldin A plus 1  $\mu$ M (p56, p79) or 10  $\mu$ M (p11) peptide before staining for intracellular IFN- $\gamma$  (Pep $\gamma$  assay). Spleen and MLN samples were first enriched for the CD8<sup>+</sup> T-cell subset by *in vitro* depletion of CD4<sup>+</sup>, MHC class II<sup>+</sup>, and Ig<sup>+</sup> cells. (*a*) BAL, (*b*) MLN, (*c*) spleen, (*d*) blood, (*e*) spleen V $\beta$ 4<sup>+</sup> and (*f*) blood V $\beta$ 4<sup>+</sup>. Reproduced from Stevenson *et al.* (1999a).

It now seems unlikely, however, that the dramatic and prolonged increase in V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell numbers following MHV-68 infection is directly comparable with human IM. Tetramer studies of EBV infection have shown that the activated CD8<sup>+</sup> set in blood consists largely of conventional, EBV-specific, MHC class I-restricted T cells (Callan *et al.* 1998). Increased numbers of V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T cells are found in a variety of MHC-different mouse strains following infection with MHV-68 and, at least for the H-2<sup>b</sup> haplotype, are not associated with known antigenic peptide epitopes (Coppola *et al.* 1999; Stevenson *et al.* 1999a). The proportion of MHV-68-specific CD8<sup>+</sup> T cells in the spleen and peripheral blood lymphocyte (PBL) pool (figure 1*c,d*) in fact drops, concurrently with the V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell expansion (figure 1*e,f*).

Another possibility was that the V $\beta$ 4 TCR chain might bind to some 'superantigen' encoded by MHV-68 (Tripp




Figure 2. The CD4<sup>+</sup> T-cell response. The B6 mice were infected i.n. with 600 plaque-forming units of MHV-68 and CLN, MLN and spleen cells from individual animals were incubated for 48 h in the IFN- $\gamma$  ELISpot assay. The numbers of MHV-68-specific CD4<sup>+</sup> T cells in each organ were determined from the frequency, the percentage of CD4<sup>+</sup> T cells, and total cell count. Each data point represents an individual mouse. The results were compiled from four experiments, indicated by the different symbols. (*a*) CLN, (*b*) MLN and (*c*) spleen. Reproduced from Christensen & Doherty (1999).

*et al.* 1997). One difference from classical superantigen-driven responses (Scherer *et al.* 1993) is that the expansion of this V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> set tends to be oligoclonal, at least within individual mice (Hardy *et al.* 2000). Also, if there is some direct interaction between the V $\beta$ 4 TCR and a viral protein, this does not seem to be mediated via binding to MHC glycoproteins, the defining characteristic of the superantigens (Coppola *et al.* 1999). The V $\beta$ 4<sup>+</sup> expansion is also seen in the small set of CD8<sup>+</sup> T cells found in MHC class I-deficient  $\beta$ 2m<sup>-/-</sup> mice (Stevenson *et al.* 1999a). Spleen populations that are completely MHC-negative can stimulate V $\beta$ 4<sup>+</sup> hybridoma cell lines generated from MHV-68-infected mice, with the optimal effect being observed at the peak of viral latency.

The *in vivo* V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell expansion in mice recovering from the acute phase of MHV-68 infection is, however, dependent both on CD40 ligand (CD40L)-mediated CD4<sup>+</sup> T-cell help and on the presence of

B lymphocytes (Brooks *et al.* 1999; Flano *et al.* 1999). The effect is not seen in lymphotoxin- $\alpha$ -deficient (LT- $\alpha^{-/-}$ ) mice (Lee *et al.* 2000), but this could be more a function of the disruption of lymphoid tissue architecture resulting from the absence of LT- $\alpha$  throughout development than a direct consequence of the absence of this cytokine. The V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell response in MHV-68 infection thus represents an intriguing phenomenon that is not clearly understood and does not, at least at this stage, seem comparable with any other known biological system.

#### 4. THE CD4<sup>+</sup> T-CELL RESPONSE

Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells are important for the control of MHV-68 infection. Sorting out the role of CD4<sup>+</sup> T cells in disease processes has, in the past, often been confounded by the need to distinguish between the part played by T-cell help in the promotion of a high-quality B-cell response and the possibility that the CD4<sup>+</sup> T cells themselves are acting directly as effectors of CMI. This difficulty was overcome with the development of Ig<sup>-/-</sup>  $\mu$ MT mice, which lack both B lymphocytes and antibody (Kitamura *et al.* 1991).

##### (a) *IFN- $\gamma$ and CD4<sup>+</sup> T-cell effector function*

Respiratory challenge of  $\mu$ MT mice with MHV-68 leads to the development of lytic infection in the lung which is essentially comparable with that in Ig<sup>+/+</sup> controls, although the extent of latency in the lymphoid tissue is less because of the lack of B lymphocytes (Weck *et al.* 1996; Usherwood *et al.* 1996b). Depleting MHV-68-infected  $\mu$ MT mice with mAbs to the CD4<sup>+</sup> and CD8<sup>+</sup> subsets resulted in the prolongation of MHV-68 replication in both cases, while the consequence of removing both lymphocyte populations simultaneously was (as might be expected) death (Christensen *et al.* 1999).

Further depletion of the CD8-depleted group with a mAb to IFN- $\gamma$  greatly compromised the extent of CD4<sup>+</sup> T-cell-mediated control, indicating that IFN- $\gamma$  production was central to the function of the CD4<sup>+</sup> subset (Christensen *et al.* 1999). Just what the IFN- $\gamma$  is doing has not been worked out, although substantial levels of this cytokine are detected in the fluid obtained from the infected lung by BAL. Also, experiments with irradiated, bone marrow (BM)-grafted chimeric mice lacking the MHC class II gene expression in radiation-resistant lung epithelium but not in radiation-sensitive macrophages and other haemopoietic cells indicated that it is important for the CD4<sup>+</sup> effectors to make direct contact with the cells that are supporting virus growth (Christensen *et al.* 1999). This is totally different from the situation for the influenza-A viruses, where IFN- $\gamma$  production does not seem to be very important (Price *et al.* 2000a) and the role of the virus-specific CD4<sup>+</sup> population seems mainly to provide T-cell help for both the B-cell and the CD8<sup>+</sup> T-cell responses (Topham *et al.* 1996; Topham & Doherty 1998a).

Both CD4<sup>+</sup> T cells and IFN- $\gamma$  seem also to be important for the control of persistent MHV-68 infection. This prominent role for IFN- $\gamma$  production by CD4<sup>+</sup> T cells in limiting both the lytic and latent phases of MHV-68 infection in  $\mu$ MT mice should not be too surprising, although it has received comparatively little attention

from those studying immunity to EBV. The same CD4-IFN- $\gamma$  role has also been identified in the control of murine cytomegalovirus infection, and in the mouse herpes simplex ocular inflammation model (Presti *et al.* 1998; Smith *et al.* 1994; Lucin *et al.* 1992; Polic *et al.* 1998; Yu *et al.* 1996).

##### (b) *CD4<sup>+</sup> T-cell help*

The development of a high-quality antibody response to MHV-68 infection is totally dependent on the concurrent presence of CD4<sup>+</sup> T cells (Sangster *et al.* 2000). This is covered below (§ 5) in the discussion of the B-cell response. On the other hand, the experiments with CD4-deficient, MHC class II<sup>-/-</sup> mice (see § 3(b)) did not provide any clear indication that CD4<sup>+</sup> T-cell help is particularly important for either the generation or maintenance of the MHV-68-specific CD8<sup>+</sup> T-cell response (Stevenson *et al.* 1998). The fact that the MHC II<sup>-/-</sup> mice eventually die from MHV-68 infection could equally be explained by the absence of CD4<sup>+</sup> effector T cells producing IFN- $\gamma$  (see § 4(a)). We are, however, still looking to see if we can find any evidence of defective functional capacity for the virus-specific CD8<sup>+</sup> T cells in MHV-68-infected MHC II<sup>-/-</sup> mice that have developed the late-onset wasting disease. This is of some interest because of the obvious parallel with EBV and HHV-8 reactivations and virus-associated oncogenesis in CD4-deficient, HIV-infected individuals with advanced acquired immune deficiency syndrome (AIDS).

As discussed above (§ 3(c)), CD40-CD40L-mediated T-cell help is essential to drive the proliferation of the unusual V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> population that dominates the IM-like phase of MHV-68 infection (Brooks *et al.* 1999; Flano *et al.* 1999). The experiments that have been done so far suggest that the V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T-cell expansion also depends on the presence of B cells. A highly speculative scenario is that the MHV-68-specific CD4<sup>+</sup> T cells interact with  $\alpha$ -MHC class II glycoprotein-presenting MHV-68 peptide(s) on an infected B cell. This then results in the production of cytokines that promote the expansion of V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> T cells that bind directly (via the TCR V $\beta$ 4 chain) to an MHV-68 protein (or some abnormally expressed host component) on the surface membrane of the infected B lymphocyte, or some other cell type. This process does not seem to depend on IFN- $\gamma$  production by the CD4<sup>+</sup> T cells.

##### (c) *Specificity and quantification of the MHV-68-specific CD4<sup>+</sup> T-cell response*

The search for MHV-68 peptides presented by MHC class II glycoproteins to CD4<sup>+</sup> T cells has not been particularly productive, despite a fair amount of effort. The only published epitope to date is the gp150<sub>139-155</sub> peptide, which binds to H2IA<sup>b</sup> and is derived from one of the viral surface glycoproteins (Liu *et al.* 1999b). The absence of a spectrum of viral peptides means that neither the tetramers nor the intracellular IFN- $\gamma$ -staining strategies used to measure the magnitude of the CD8<sup>+</sup> T-cell response (see § 3(a)) have been available for the CD4<sup>+</sup> subset. Quantitative analysis of the CD4<sup>+</sup> T-cell response has relied instead on short-term *in vitro* culture with whole virus, followed by frequency determination using the single-cell IFN- $\gamma$  ELISpot assay (Christensen & Doherty




Figure 3. The AFC response. The kinetics of virus-specific AFC responses in the CLN (a), MLN (b), spleen (c) and BM (d) were determined for B6 mice infected i.n. with MHV-68. The ELISpot assay used purified MHV-68 as the immunoabsorbent to measure the number of cells producing virus-specific IgM, IgA, IgG1, IgG2a, IgG2b and IgG3 at different times after infection. Results are expressed as the number of AFC per  $1 \times 10^5$  or  $5 \times 10^5$  nucleated cells. The mean + s.e. is shown for three to six individual mice. Cells sampled from days 6–35 post-infection were also assayed on plates coated with influenza virus antigens as control for non-specific binding. Small numbers of IgM AFC (0–12 AFC per  $1 \times 10^5$  for CLN, MLN, and spleen; 0–48 AFC per  $5 \times 10^5$  for the BM), and essentially no AFC producing switched isotypes, were detected on these control plates. Reproduced from Sangster *et al.* (2000).

1999). Earlier LDA experiments used interleukin-2 (IL-2) production as a read-out. The results from these studies are qualitatively similar to the finding from the ELISpot analysis, although, as with the LDA for CD8<sup>+</sup> T cells (§ 3(b)), the numbers tend to be lower.

The MHV-68-specific population peaks at about 1:20–1:50 of the CD4<sup>+</sup> set during the acute phase of the infectious process, with evidence of clonal expansion being found in both the MLN and the spleen (Christensen & Doherty 1999). Frequencies of about 1:200–1:500 are then maintained in the long term. Furthermore, cell sorting followed by ELISpot analysis indicates that the MHV-68-

specific CD4<sup>+</sup> T cells retain an 'activated' CD62L<sup>lo</sup> CD44<sup>hi</sup> phenotype indefinitely. This is different from the situation for the readily eliminated Sendai virus (Ewing *et al.* 1995; Topham & Doherty 1998b), where much of the CD4<sup>+</sup> set reverts to being CD62L<sup>hi</sup>, and is consistent with the profile that would be expected for a persistent infection.

## 5. THE B-CELL RESPONSE

Perhaps the most obvious feature of MHV-68 infection is the massive splenomegaly that peaks between 14 and 21 days after i.n. infection (Usherwood *et al.* 1996a). The greatest increase in cell numbers is observed for the B220<sup>+</sup> B-lymphocyte population, although the CD4<sup>+</sup> and CD8<sup>+</sup> (§ 3(c)) sets are also substantially expanded. The net consequence is that all three populations are maintained at higher prevalence in the PBL pool for at least five weeks after MHV-68 challenge (Doherty *et al.* 1997a). The *in vivo* expansion of the B220<sup>+</sup> population is, as with the proliferation of the V $\beta$ 4<sup>+</sup>CD8<sup>+</sup> set (§ 3(c)), totally dependent on concurrent CD40L-mediated CD4<sup>+</sup> T-cell help (Cardin *et al.* 1996; Brooks *et al.* 1999; Flano *et al.* 1999). Also, although the prominence of the CD8<sup>+</sup> T cells in the circulation gives the appearance of an IM-like syndrome (§ 3(c)), the effect is relative; all categories of lymphocytes are proliferating and show higher blood counts for a prolonged interval (Hamilton-Easton *et al.* 1999). These findings have intriguing implications for models of lymphocyte homeostasis (Doherty *et al.* 1997a).

### (a) Proliferation *in vitro*, but without transformation

A somewhat different, CD4-independent phenomenon is observed when B cells are infected *in vitro* with MHV-68. The lymphocytes proliferate, express higher levels of CD69 on the cell surface, produce substantial amounts of IL-6 and IgM, then die after about 72 h (Stevenson & Doherty 1999). The presence of IL-6 is not mandatory, and the same activation effect is seen for MHV-68 infection of IL-6<sup>-/-</sup> and IL-6<sup>+/+</sup> B cells, or B cells cultured with MHV-68 in the presence or absence of a mAb to this cytokine. Also, although these MHV-68-infected B lymphocytes all die, there is no evidence of productive (lytic) infection. The latency-associated MHV-68 tRNAs (but not the M2 gene) are transcribed, while the viral DNA remains linear and shows little of the tendency to circularize that is characteristic of  $\gamma$ -herpesvirus persistence (Dutia *et al.* 1999b). Numerous attempts have failed to promote the emergence *in vitro* of 'immortalized' B-cell clones, although it should be noted that only one MHV-68 isolate has yet been analysed in any detail.

### (b) Specific and non-specific Ig production *in vivo*

The CD4-dependent, polyclonal B-cell activation that follows MHV-68 infection is accompanied by a massive, class-switched Ig response, much of which is clearly not specific for the virus (Stevenson & Doherty 1998; Sangster *et al.* 2000). This was measured as  $\mu\text{g ml}^{-1}$  of serum Ig and by counting antibody-forming cells (AFCs) producing the  $\kappa$  light chain used by 90% of mouse Ig. At the peak of the acute response in the MLN, the numbers of  $\kappa$ -producing AFCs detected by ELISpot analysis were



more than 200-fold higher than those making antibody specific for purified MHV-68 (figure 3). Both spectrometry and the constancy of  $\kappa/\lambda$  ratios indicated that this total serum Ig response, which was not significantly reduced in level by adsorption with purified virus, is indeed very polyclonal.

The numbers of MHV-68-specific AFCs peaked first in the MLN (figure 3*b*), then later in the CLN and spleen (figure 3*a,c*). The AFC response in the lymph nodes draining the respiratory mucosa was somewhat delayed, and of smaller magnitude when compared with that observed following i.n. infection with readily eliminated, negative-strand RNA viruses like influenza or murine parainfluenza type 1 (Sendai). Many of the AFCs producing antibody to MHV-68 were, as with other infections (Hyland *et al.* 1994; Slifka & Ahmed 1996), found in BM in the long term (figure 3*d*). There was no indication that the B-cell response to MHV-68 is being constantly stimulated as a consequence of virus reactivation to lytic phase.

An intriguing feature is that the distribution of the isotype patterns was characteristic of the Ig response overall, independent of specificity for the virus. The same IgG2a and IgG2b dominance was found for both virus-specific (figure 3) and total Ig profiles, determined by serum and AFC analysis. This suggests that the cytokines, and other molecular interactions that determine class switching, are operating in comparable ways for the MHV-68-specific and non-specific responses. Another unusual feature of MHV-68 infection in B6 mice is that virus-specific IgA-producing AFCs and serum IgA were, when compared with the situation for other respiratory viruses (Sangster *et al.* 1997), remarkably absent during the acute phase of the disease process.

#### (c) *Can MHV-68 trigger autoimmunity?*

Levels of Ig specific for double-stranded (ds) DNA and for type II collagen were increased in some, although not in all, MHV-68-infected B6 mice (Sangster *et al.* 2000). On the other hand, mice that had been immunized previously with an influenza-A virus showed a relative fall in serum antibody levels specific for this virus, suggesting that the massive total Ig response to MHV-68 accelerated the rate of clearance of the influenza-specific Ig. There is thus no indication that MHV-68 causes cross-reactive stimulation of memory B cells, although this needs to be looked at again using single-cell assays. Clearly, the nature of the Ig response induced by this virus merits further analysis, particularly from the aspect of determining the nature of the molecular events underlying the polyclonal B-cell activation and class-switched Ig production.

#### (d) *Is antibody involved in the control of viral persistence?*

The MHC class II<sup>-/-</sup> mice that lack CD4<sup>+</sup> T cells seem first to control MHV-68 infection, then show evidence of reversion to lytic phase and death within three to four months of the initial virus challenge (Cardin *et al.* 1996). This could be attributed to the lack of IFN- $\gamma$ -producing CD4<sup>+</sup> T-cell effectors, or to the absence of a class-switched, virus-specific Ig response. The fact that Ig<sup>-/-</sup>  $\mu$ MT mice do not develop the wasting disease seen

in the MHC II<sup>-/-</sup> group does not exclude a role for antibody as, due to the lack of B cells, the extent of MHV-68 persistence is lower in these animals. Set against this argument is other evidence suggesting that the lytic and latent phases of MHV-68 infection seem, once established, to be relatively independent.

Mice were thymectomized as adults (to prevent renewal of the T-cell pool), infected with MHV-68 and allowed to recover (Stevenson *et al.* 1999*c*). They were then depleted of both the major T-cell subsets by treatment, for a time, with mAbs to CD4 and CD8, a procedure that is lethal if performed prior to virus challenge. These mice remained clinically normal, and showed no evidence for the reactivation of lytic MHV-68 infection or an increase in the numbers of latently infected cells. Unfortunately, the mAb-depletion protocol did not remove all representatives of the CD4<sup>+</sup> and CD8<sup>+</sup> subsets in the very long term, and the experiment probably merits repeating now that we have sensitive assays for MHV-68-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Stevenson *et al.* 1999*a*; Christensen & Doherty 1999). Even so, the possibility that antibody plays a part in the control of the persistent phase of this infectious process cannot, at this stage, be discounted.

## 6. CYTOKINES AND CHEMOKINES

Cytokines and chemokines are likely to be enormously important for the control of this large DNA virus. It is very clear that type 1 IFNs (IFN- $\alpha\beta$ ) are essential, early mediators of MHV-68 resistance (Dutia *et al.* 1999*a*). Lung titres were 100- to 1000-fold higher in IFN- $\alpha\beta$  receptor (R)<sup>-/-</sup> mice, which succumbed to a relatively low-dose challenge. The numbers of latently infected spleen cells were also increased tenfold in IFN- $\alpha\beta$ R<sup>-/-</sup> mice, at least during the acute phase of the infection.

Lymphocytes recovered directly from MHV-68-infected B6 mice were found to produce substantial amounts of IFN- $\gamma$  and IL-6, with lower levels of IL-10 and IL-2 being detected following *in vitro* culture (Sarawar *et al.* 1996). The 'Th2' lymphokines, IL-4 and IL-5, seem to be minimally expressed in this infection. Virus growth and control profiles were essentially normal in IL-6<sup>-/-</sup> mice (Sarawar *et al.* 1998), although there was evidence of enhanced natural killer cell activity early in the course of the infection. Otherwise intact IFN- $\gamma$ <sup>-/-</sup> mice are not obviously compromised during the acute phase of the disease process (Sarawar *et al.* 1997). The same is true for LT- $\alpha$ <sup>-/-</sup> mice, despite the extreme disruption of normal lymph node and splenic architecture that results from the absence of this cytokine throughout ontogeny (Lee *et al.* 2000). Both IFN- $\gamma$ <sup>-/-</sup> and IFN- $\gamma$ R<sup>-/-</sup> mice develop abnormal pathology in the longer term, particularly associated with persistent MHV-68 replication in the smooth muscle cells of the large arteries (Dal Canto & Virgin 1999; Weck *et al.* 1997). This leads in turn to thickening of the blood vessel wall and narrowing of the arterial lumen, with eventual vascular occlusion and death. The MHV-68-infected IFN- $\gamma$ R<sup>-/-</sup> animals can also show evidence of acute splenic atrophy, although the mechanism is yet to be clarified (Dutia *et al.* 1997).

The virus makes a chemokine-binding protein (M3), the role of which is currently being established by




Figure 4. Effect of post-exposure vaccination on CD8<sup>+</sup> T-cell numbers. The IA<sup>b+/+</sup> B6 mice were infected i.n. with MHV-68 one month prior to i.p. challenge with the recombinant vacc viruses, vacc-p56, vacc-p79 or a vacc-LCMV<sup>b</sup> control. The numbers of virus-specific CD8<sup>+</sup> T cells in spleen were determined by staining with the D<sup>b</sup>p56 or K<sup>b</sup>p79 tetramers (a,b) or by the Pep $\gamma$  assay (c,d). Reproduced from Belz *et al.* (2000).

experiments with an M3-deletion mutant (Parry *et al.* 2000; Van Berkel *et al.* 1999). This protein binds all subfamilies of chemokines in solution, thus inhibiting interaction with the appropriate receptors. The blocking effect is seen for the human CC and CXC chemokines, suggesting that the molecule may be of therapeutic value. The development of such a product would surely be a 'first' for experiments that have focused exclusively on a mouse model of viral pathogenesis!

## 7. EFFICACY OF IMMUNIZATION

Most of the vaccines that are currently used to protect human populations against virus infections work by promoting an antibody response. The virus-specific Ig functions to minimize the extent of virus replication at the point of entry and/or prevents dissemination via the blood. Mice were injected subcutaneously with a vaccinia (vacc) virus construct incorporating the MHV-68 gp150 gene (equivalent to EBV gp350), then challenged i.n. with MHV-68 (Stewart *et al.* 1999). Prior exposure to vacc-gp150 greatly diminished the extent of lytic infection, and virtually abrogated the development of the IM-like disease. However, the virus still established latency.

### (a) Pre-exposure priming of CD8<sup>+</sup> T cells

The question of whether or not it is possible to control virus infections by priming only the CD8<sup>+</sup> T-cell response is currently of considerable interest, particularly from the aspect that such a vaccine might circumvent virus variation as a consequence of antibody-mediated selection processes. This is clearly important with the lentiviruses and the influenza-A viruses, although there is also evidence from both systems that a continuing (Price *et al.* 2000b) CD8<sup>+</sup> T-cell response can drive the emergence of viral escape mechanisms (Chen *et al.* 2000). Experiments with the influenza-A viruses have shown that the recall of a very large memory CD8<sup>+</sup> T-cell population can indeed limit virus replication, but the infectious process still

becomes established in the lung and the protective effect is not obvious until about two to three days after virus challenge (Christensen *et al.* 2000).

Prime and boost experiments with vacc-p56 and influenza virus (WSN-p56) recombinants led to the development of a massive response to the D<sup>b</sup>-restricted p56 epitope of MHV-68 (Stevenson *et al.* 1999b). This caused almost complete control of the lytic phase in the lung, and initially reduced the magnitude of latent infection in the lymphoid tissue. Within three weeks, however, there were as many persistently infected cells in the spleens of the primed and naive (prior to MHV-68 challenge) mice, and the IM-like disease (although delayed) also developed. Similar results were found in mice that had been immunized by the injection of dendritic cells pulsed with the peptides that stimulate MHV-68-specific CD8<sup>+</sup> T cells (Liu *et al.* 1999b). This analysis also included the one MHV-68 peptide known to be recognized by CD4<sup>+</sup> T cells, but the fact that there was no additional effect cannot be regarded as an adequate test of the consequences of priming the CD4 compartment. At this stage, what can be said with a reasonable level of certainty is that the establishment of a  $\gamma$ -herpesvirus infection cannot be prevented by priming only CD8<sup>+</sup> T cells specific for lytic-phase epitopes.

### (b) Post-exposure vaccination

The fact that priming the CD8<sup>+</sup> T-cell response prior to i.n. MHV-68 challenge greatly diminished the extent of virus replication in the lung caused us to question whether it might be possible to modulate the reactivation of lytic infection in MHC class II<sup>-/-</sup> mice by vaccinating after the virus had become established (Belz *et al.* 2000). Post-exposure challenge of MHV-68-infected MHC II<sup>+/+</sup> (figure 4) and MHC II<sup>-/-</sup> mice with vacc-p56 or vacc-p79 caused a dramatic increase in the numbers of CD8<sup>+</sup> T-cells specific for D<sup>b</sup>p56 or K<sup>b</sup>p79, respectively. This was an intriguing result as we were, at least in the MHC II<sup>-/-</sup> mice, introducing the recombinant vacc viruses into a

situation where the reactivation of MHV-68 to lytic phase should be constantly boosting the CD8<sup>+</sup> T-cell response. Clearly, the vacc-p56 challenge in some way broke through the constraints regulating the magnitude of any such restimulation by persistent MHV-68.

The net consequence of this boost was, however, that the MHV-68-infected MHC II<sup>-/-</sup> mice survived (on average) for only a few weeks longer. All the secondarily stimulated mice eventually succumbed when the size of the MHV-68-specific CD8<sup>+</sup> T-cell set fell to the level (still more than 5% of the splenic CD8<sup>+</sup> population) found in the unmanipulated, MHV-68-infected MHC II<sup>-/-</sup> controls. Perhaps this reflects that the capacity of effector CD8<sup>+</sup> T cells to eliminate lytically infected targets by direct cell–cell interaction is limited by the capacity of the viral K3 gene to modulate epitope presentation. The CD8<sup>+</sup> T cells also produce IFN- $\gamma$ , which, when virus-specific CD8<sup>+</sup> T-cell numbers are high, might be available at sufficient concentration to mimic the IFN- $\gamma$ -dependent protective mechanism used by CD4<sup>+</sup> T cells, whatever that may be.

## 8. CONCLUSIONS

This experimental model has already provided us with a spectrum of novel information about the nature of  $\gamma$ -herpesvirus infections, and is likely to continue to do so. One of the more surprising insights to date is that there is no obvious correlation between the extent of the initial replicative infection and the level of MHV-68 latency in the long term. This message comes through from the vaccination experiments (Stevenson *et al.* 1999b), and from the consequences of infecting mice with viral mutants that lack functional genes important for either lytic infection or viral persistence (Clambey *et al.* 2000).

The quantitative protocols that have been developed for the analysis of the CD8<sup>+</sup>, CD4<sup>+</sup> and B-cell responses to MHV-68 offer a unique experimental system for analysing the consequences of various manipulations that may promote (or compromise) immunity to large, persistent DNA viruses. The finding that CD4<sup>+</sup> T cells producing IFN- $\gamma$  are very important for the control of MHV-68 infection (Christensen *et al.* 1999) should cause us to think more seriously about this aspect of the host response to the human  $\gamma$ -herpesviruses. Is the reactivation of EBV to lytic phase and the oncogenesis associated with both EBV and HHV-8 in AIDS patients a function of the loss of CD4<sup>+</sup> T-cell help for the CD8 response, or a direct consequence of the lack of CD4<sup>+</sup> T-cell effectors?

Even so, it is clear that MHV-68 is neither EBV nor HHV-8. The latency-associated transcripts that are so central to EBV immunity and pathogenesis seem to be absent from, or as yet undetected in, cells that are persistently infected with MHV-68. Although there is one lymphoma line carrying MHV-68, the virus does not readily cause cell transformation. However, we do not know what happens in the bank vole, the species from which this virus was originally isolated, and it is possible that there are natural variants that may be oncogenic in mice.

Perhaps the most useful, general message that emerges from the experiments to date with MHV-68 is that all the key elements of immunity are required to control  $\gamma$ -herpesvirus infections. As with other, large DNA viruses,

these pathogens have developed a spectrum of immune subversion strategies. The K3 molecules of HHV-8 and MHV-68 diminish the effectiveness of antigen presentation by MHC class I glycoproteins (Stevenson *et al.* 2000; Ishido *et al.* 2000; Coscoy & Ganem 2000). The MHV-68 genome encodes an inhibitor of complement activation (Kapadia *et al.* 1999). The MHV-68 chemokine-binding protein (M3) and the M11 protein (Wang *et al.* 1999) that inhibits apoptosis are likely to have a broad effect on both antigen-specific and non-specific elements of the host response. An optimal  $\gamma$ -herpesvirus vaccine should generate memory in the CD8<sup>+</sup> T-cell, CD4<sup>+</sup> T-cell and B-cell compartments.

Most of the experiments identified with the authors of this article were done in Memphis, and were supported by the American Lebanese Syrian Associated Charities (ALSAC), and by US National Institutes of Health grants AI29579 and CA21765. We thank Vicki Henderson for help with the manuscript.

## REFERENCES

- Alexander, L., Denekamp, L., Knapp, A., Auerbach, M. R., Damania, B. & Desrosiers, R. C. 2000 The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. *J. Virol.* **74**, 3388–3398.
- Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. & Davis, M. M. 1996 Phenotypic analysis of antigen-specific T lymphocytes. *Science* **274**, 94–96.
- Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. 1998 EBV persistence in memory B cells *in vivo*. *Immunity* **9**, 395–404.
- Belz, G. T., Stevenson, P. G., Castrucci, M. R., Altman, J. D. & Doherty, P. C. 2000 Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8<sup>+</sup> T cells but confers minimal survival advantage on CD4-deficient mice. *Proc. Natl Acad. Sci. USA* **97**, 2725–2730.
- Blaskovic, D., Stancekova, M., Svobodova, J. & Mistrikova, J. 1980 Isolation of five strains of herpesviruses from two species of free living small rodents. *Acta Virol.* **24**, 468.
- Brooks, J. W., Hamilton-Easton, A. M., Christensen, J. P., Cardin, R. D., Hardy, C. L. & Doherty, P. C. 1999 Requirement for CD40 ligand, CD4<sup>+</sup> T cells, and B cells in an infectious mononucleosis-like syndrome. *J. Virol.* **73**, 9650–9654.
- Callan, M. F., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D., O'Callaghan, C. A., Steven, N., McMichael, A. J. & Rickinson, A. B. 1998 Direct visualization of antigen-specific CD8<sup>+</sup> T cells during the primary immune response to Epstein–Barr virus *in vivo*. *J. Exp. Med.* **187**, 1395–1402.
- Cardin, R. D., Brooks, J. W., Sarawar, S. R. & Doherty, P. C. 1996 Progressive loss of CD8<sup>+</sup> T cell-mediated control of a gamma-herpesvirus in the absence of CD4<sup>+</sup> T cells. *J. Exp. Med.* **184**, 863–871.
- Chang, J., Renne, R., Dittmer, D. & Ganem, D. 2000 Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. *Virology* **266**, 17–25.
- Chen, Z. W., Craiu, A., Shen, L., Kuroda, M. J., Iroku, U. C., Watkins, D. I., Voss, G. & Letvin, N. L. 2000 Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. *J. Immunol.* **164**, 6474–6479.

- Christensen, J. P. & Doherty, P. C. 1999 Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gammaherpesvirus. *J. Virol.* **73**, 4279–4283.
- Christensen, J. P., Marker, O. & Thomsen, A. R. 1994 The role of CD4<sup>+</sup> T cells in cell-mediated immunity to LCMV: studies in MHC class I and class II deficient mice. *Scand. J. Immunol.* **40**, 373–382.
- Christensen, J. P., Cardin, R. D., Branum, K. C. & Doherty, P. C. 1999 CD4<sup>+</sup> T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. *Proc. Natl Acad. Sci. USA* **96**, 5135–5140.
- Christensen, J. P., Doherty, P. C., Branum, K. C. & Riberdy, J. M. 2000 Profound protection against respiratory challenge with a lethal H7N7 Influenza A virus by increasing the magnitude of CD8<sup>+</sup> T-cell memory. *J. Virol.* **74**, 11 690–11 696.
- Clambey, E. T., Virgin, H. W. & Speck, S. H. 2000 Disruption of the murine gammaherpesvirus 68 M1 open reading frame leads to enhanced reactivation from latency. *J. Virol.* **74**, 1973–1984.
- Coppola, M. A., Flano, E., Nguyen, P., Hardy, C. L., Cardin, R. D., Shastri, N., Woodland, D. L. & Blackman, M. A. 1999 Apparent MHC-independent stimulation of CD8<sup>+</sup> T cells *in vivo* during latent murine gammaherpesvirus infection. *J. Immunol.* **163**, 1481–1489.
- Coscoy, L. & Ganem, D. 2000 Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. *Proc. Natl Acad. Sci. USA* **97**, 8051–8056.
- Dal Canto, A. J. & Virgin, H. W. 1999 Animal models of infection-mediated vasculitis. *Curr. Opin. Rheumatol.* **11**, 17–23.
- Doherty, P. C. 1998 The numbers game for virus-specific CD8<sup>+</sup> T cells. *Science* **280**, 227.
- Doherty, P. C. & Christensen, J. P. 2000 Accessing complexity: the dynamics of virus-specific T cell responses. *A. Rev. Immunol.* **18**, 561–592.
- Doherty, P. C., Allan, W., Eichelberger, M. & Carding, S. R. 1992 Roles of alpha beta and gamma delta T cell subsets in viral immunity. *A. Rev. Immunol.* **10**, 123–151.
- Doherty, P. C., Topham, D. J. & Tripp, R. A. 1996 Establishment and persistence of virus-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell memory. *Immunol. Rev.* **150**, 23–44.
- Doherty, P. C., Hamilton-Easton, A. M., Topham, D. J., Riberdy, J., Brooks, J. W. & Cardin, R. D. 1997a Consequences of viral infections for lymphocyte compartmentalization and homeostasis. *Semin. Immunol.* **9**, 365–373.
- Doherty, P. C., Topham, D. J., Tripp, R. A., Cardin, R. D., Brooks, J. W. & Stevenson, P. G. 1997b Effector CD4<sup>+</sup> and CD8<sup>+</sup> T-cell mechanisms in the control of respiratory virus infections. *Immunol. Rev.* **159**, 105–117.
- Dutia, B. M., Clarke, C. J., Allen, D. J. & Nash, A. A. 1997 Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: a role for CD8 T cells. *J. Virol.* **71**, 4278–4283.
- Dutia, B. M., Allen, D. J., Dyson, H. & Nash, A. A. 1999a Type I interferons and IRF-1 play a critical role in the control of a gammaherpesvirus infection. *Virology* **261**, 173–179.
- Dutia, B. M., Stewart, J. P., Clayton, R. A., Dyson, H. & Nash, A. A. 1999b Kinetic and phenotypic changes in murine lymphocytes infected with murine gammaherpesvirus-68 *in vitro*. *J. Gen. Virol.* **80**, 2729–2736.
- Efstathiou, S., Ho, Y. M. & Minson, A. C. 1990 Cloning and molecular characterization of the murine herpesvirus 68 genome. *J. Gen. Virol.* **71**, 1355–1364.
- Egan, M. A. (and 12 others) 2000 Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. *J. Virol.* **74**, 7485–7495.
- Ehlers, B., Ulrich, S. & Goltz, M. 1999 Detection of two novel porcine herpesviruses with high similarity to gammaherpesviruses. *J. Gen. Virol.* **80**, 971–978.
- Ehtisham, S., Sunil-Chandra, N. P. & Nash, A. A. 1993 Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. *J. Virol.* **67**, 5247–5252.
- Ensser, A., Pflanz, R. & Fleckenstein, B. 1997 Primary structure of the alcelaphine herpesvirus 1 genome. *J. Virol.* **71**, 6517–6525.
- Epstein, M. A. 1986 Vaccination against Epstein–Barr virus: current progress and future strategies. *Lancet* **1**, 1425–1427.
- Ewing, C., Topham, D. J. & Doherty, P. C. 1995 Prevalence and activation phenotype of Sendai virus-specific CD4<sup>+</sup> T cells. *Virology* **210**, 179–185.
- Falk, K., Rotzschke, O., Deres, K., Metzger, J., Jung, G. & Rammensee, H. G. 1991 Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. *J. Exp. Med.* **174**, 425–434.
- Flano, E., Woodland, D. L. & Blackman, M. A. 1999 Requirement for CD4<sup>+</sup> T cells in V $\beta$ 4<sup>+</sup> CD8<sup>+</sup> T cell activation associated with latent murine gammaherpesvirus infection. *J. Immunol.* **163**, 3403–3408.
- Gompels, U. A., Craxton, M. A. & Honess, R. W. 1988 Conservation of gene organization in the lymphotropic herpesviruses herpesvirus Saimiri and Epstein–Barr virus. *J. Virol.* **62**, 757–767.
- Greensill, J., Sheldon, J. A., Renwick, N. M., Beer, B. E., Norley, S., Goudsmit, J. & Schulz, T. F. 2000 Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among Old World primates? *J. Virol.* **74**, 1572–1577.
- Grusby, M. J., Johnson, R. S., Papaioannou, V. E. & Glimcher, L. H. 1991 Depletion of CD4<sup>+</sup> T cells in major histocompatibility complex class II-deficient mice. *Science* **253**, 1417–1420.
- Gulland, F. M., Reid, H. W., Buxton, D., Lewis, J. C., Kock, R. A. & Kirkwood, J. K. 1989 Malignant catarrhal fever in a roan antelope (*Hippotragus equinus*) at Regent's Park. *Vet. Rec.* **124**, 42–43.
- Hamilton-Easton, A. M., Christensen, J. P. & Doherty, P. C. 1999 Turnover of T cells in murine gammaherpesvirus 68-infected mice. *J. Virol.* **73**, 7866–7869.
- Hardy, C. L., Silins, S. L., Woodland, D. L. & Blackman, M. A. 2000 Murine  $\gamma$ -herpesvirus infection causes V $\beta$ 4-specific CDR3-restricted clonal expansions within CD8<sup>+</sup> peripheral blood T lymphocytes. *Int. Immunol.* **12**, 1193–1204.
- Henle, G., Henle, W. & Diehl, V. 1968 Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. *Proc. Natl Acad. Sci. USA* **59**, 94–101.
- Holloway, S. A., Lindquister, G. J., Studdert, M. J. & Drummer, H. E. 1999 Identification, sequence analysis and characterisation of equine herpesvirus 5 glycoprotein B. *Arch. Virol.* **144**, 287–307.
- Husain, S. M., Usherwood, E. J., Dyson, H., Coleclough, C., Coppola, M. A., Woodland, D. L., Blackman, M. A., Stewart, J. P. & Sample, J. T. 1999 Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8<sup>+</sup> T lymphocytes. *Proc. Natl Acad. Sci. USA* **96**, 7508–7513.
- Hyland, L., Sangster, M., Sealy, R. & Coleclough, C. 1994 Respiratory virus infection of mice provokes a permanent humoral immune response. *J. Virol.* **68**, 6083–6086.
- Ishido, S., Wang, C., Lee, B. S., Cohen, G. B. & Jung, J. U. 2000 Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. *J. Virol.* **74**, 5300–5309.
- Jacoby, R. O., Buxton, D. & Reid, H. W. 1988 The pathology of wildebeest-associated malignant catarrhal fever in hamsters, rats and guinea-pigs. *J. Comp. Pathol.* **98**, 99–109.

- Kapadia, S. B., Molina, H., Van Berkel, V., Speck, S. H. & Virgin, H. W. 1999 Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. *J. Virol.* **73**, 7658–7670.
- Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K. 1991 A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. *Nature* **350**, 423–426.
- Kuroda, M. J., Schmitz, J. E., Charini, W. A., Nickerson, C. E., Lifton, M. A., Lord, C. I., Forman, M. A. & Letvin, N. L. 1999 Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. *J. Immunol.* **162**, 5127–5133.
- Lee, B. J., Santee, S., Von Gesjen, S., Ware, C. F. & Sarawar, S. R. 2000 Lymphotoxin- $\alpha$ -deficient mice can clear a productive infection with murine gammaherpesvirus 68 but fail to develop splenomegaly or lymphocytosis. *J. Virol.* **74**, 2786–2792.
- Li, H., Dyer, N., Keller, J. & Crawford, T. B. 2000a Newly recognized herpesvirus causing malignant catarrhal fever in white-tailed deer (*Odocoileus virginianus*). *J. Clin. Microbiol.* **38**, 1313–1318.
- Li, H., Snowden, G., O'Toole, D. & Crawford, T. B. 2000b Transmission of ovine herpesvirus 2 among adult sheep. *Vet. Microbiol.* **71**, 27–35.
- Liu, L., Flano, E., Usherwood, E. J., Surman, S., Blackman, M. A. & Woodland, D. L. 1999a Lytic cycle T cell epitopes are expressed in two distinct phases during MHV-68 infection. *J. Immunol.* **163**, 868–874.
- Liu, L., Usherwood, E. J., Blackman, M. A. & Woodland, D. L. 1999b T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. *J. Virol.* **73**, 9849–9857.
- Lucin, P., Pavic, I., Polic, B., Jonjic, S. & Koszinowski, U. H. 1992 Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. *J. Virol.* **66**, 1977–1984.
- McMichael, A. J. & O'Callaghan, C. A. 1998 A new look at T cells. *J. Exp. Med.* **187**, 1367–1371.
- Morgan, A. J., Finerty, S., Lovgren, K., Scullion, F. T. & Morein, B. 1988 Prevention of Epstein–Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. *J. Gen. Virol.* **69**, 2093–2096.
- Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D., Zajac, A. Miller, J., Slansky, J. & Ahmed, R. 1998 Counting antigen specific CD8 T cells: a reevaluation of bystander activation during viral infection. *Immunity* **8**, 177–187.
- Murali-Krishna, K., Lau, L. L., Sambhara, S., Lemonnier, F., Altman, J. & Ahmed, R. 1999 Persistence of memory CD8 T cells in MHC class I-deficient mice. *Science* **286**, 1377–1381.
- Nash, A. A. & Sunil-Chandra, N. P. 1994 Interactions of the murine gammaherpesvirus with the immune system. *Curr. Opin. Immunol.* **6**, 560–563.
- Parry, B. C., Simas, J. P., Smith, V. P., Stewart, C. A., Minson, A. C., Efstathiou, S. & Alcami, A. 2000 A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. *J. Exp. Med.* **191**, 573–578.
- Peacock, J. W. & Bost, K. L. 2000 Infection of intestinal epithelial cells and development of systemic disease following gastric instillation of murine gammaherpesvirus-68. *J. Gen. Virol.* **81**, 421–429.
- Polic, B., Hengel, H., Krmpotic, A., Trgovcich, J., Pavic, I., Luccaroni, P., Jonjic, S. & Koszinowski, U. H. 1998 Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. *J. Exp. Med.* **188**, 1047–1054.
- Pollock, J. L., Presti, R. M., Paetzold, S. & Virgin, H. W. 1997 Latent murine cytomegalovirus infection in macrophages. *Virology* **227**, 168–179.
- Presti, R. M., Pollock, J. L., Dal Canto, A. J., O'Guin, A. K. & Virgin, H. W. 1998 Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. *J. Exp. Med.* **188**, 577–588.
- Price, G. E., Gaszewska-Mastarlarz, A. & Moskophidis, D. 2000a The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. *J. Virol.* **74**, 3996–4003.
- Price, G. E., Ou, R., Jiang, H., Huang, L. & Moskophidis, D. 2000b Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia. *J. Exp. Med.* **191**, 1853–1867.
- Reid, H. W. & Rowe, L. 1973 The attenuation of a herpes virus (malignant catarrhal fever virus) isolated from hartebeest (*Alcelaphus buselaphus cokei* Gunther). *Res. Vet. Sci.* **15**, 144–146.
- Rickinson, A. B. & Kieff, E. 1996 Epstein–Barr virus. In *Fields' virology*, vol. 2, ch. 75 (ed. B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman & S. E. Straus), pp. 2397–2446. Philadelphia, PA: Lippincott-Raven.
- Rickinson, A. B. & Moss, D. J. 1997 Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. *A. Rev. Immunol.* **15**, 405–431.
- Sangster, M. Y., Mo, X. Y., Sealy, R. & Coleclough, C. 1997 Matching antibody class with pathogen type and portal of entry. *J. Immunol.* **159**, 1893–1902.
- Sangster, M. Y., Topham, D. J., D'Costa, S., Cardin, R. D., Marion, T. N., Myers, L. K. & Doherty, P. C. 2000 Analysis of the virus-specific and nonspecific B cell response to a persistent B-lymphotropic gammaherpesvirus. *J. Immunol.* **164**, 1820–1828.
- Sarawar, S. R., Cardin, R. D., Brooks, J. W., Mehrpooya, M., Tripp, R. A. & Doherty, P. C. 1996 Cytokine production in the immune response to murine gammaherpesvirus 68. *J. Virol.* **70**, 3264–3268.
- Sarawar, S. R., Cardin, R. D., Brooks, J. W., Mehrpooya, M., Hamilton-Easton, A. M., Mo, X. Y. & Doherty, P. C. 1997 Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. *J. Virol.* **71**, 3916–3921.
- Sarawar, S. R., Brooks, J. W., Cardin, R. D., Mehrpooya, M. & Doherty, P. C. 1998 Pathogenesis of murine gammaherpesvirus-68 infection in interleukin-6-deficient mice. *Virology* **249**, 359–366.
- Scherer, M. T., Ignatowicz, L., Winslow, G. M., Kappler, J. W. & Marrack, P. 1993 Superantigens: bacterial and viral proteins that manipulate the immune system. *A. Rev. Cell Biol.* **9**, 101–128.
- Simas, J. P. & Efstathiou, S. 1998 Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis. *Trends Microbiol.* **6**, 276–282.
- Slifka, M. K. & Ahmed, R. 1996 Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. *Trends Microbiol.* **4**, 394–400.
- Smith, P. M., Wolcott, R. M., Chervenak, R. & Jennings, S. R. 1994 Control of acute cutaneous *Herpes simplex* virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). *Virology* **202**, 76–88.
- Speck, S. H. & Virgin, H. W. 1999 Host and viral genetics of chronic infection: a mouse model of gamma-herpesvirus pathogenesis. *Curr. Opin. Microbiol.* **2**, 403–409.
- Stevenson, P. G. & Doherty, P. C. 1998 Kinetic analysis of the specific host response to a murine gammaherpesvirus. *J. Virol.* **72**, 943–949.
- Stevenson, P. G. & Doherty, P. C. 1999 Non-antigen-specific B-cell activation following murine gammaherpesvirus infection is CD4 independent *in vitro* but CD4 dependent *in vivo*. *J. Virol.* **73**, 1075–1079.

- Stevenson, P. G., Belz, G. T., Altman, J. D. & Doherty, P. C. 1998 Virus-specific CD8<sup>+</sup> T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice. *Proc. Natl Acad. Sci. USA* **95**, 15 565–15 570.
- Stevenson, P. G., Belz, G. T., Altman, J. D. & Doherty, P. C. 1999a Changing patterns of dominance in the CD8<sup>+</sup> T cell response during acute and persistent murine gamma-herpesvirus infection. *Eur. J. Immunol.* **29**, 1059–1067.
- Stevenson, P. G., Belz, G. T., Castrucci, M. R., Altman, J. D. & Doherty, P. C. 1999b A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. *Proc. Natl Acad. Sci. USA* **96**, 9281–9286.
- Stevenson, P. G., Cardin, R. D., Christensen, J. P. & Doherty, P. C. 1999c Immunological control of a murine gamma-herpesvirus independent of CD8<sup>+</sup> T cells. *J. Gen. Virol.* **80**, 477–483.
- Stevenson, P. G., Efstathiou, S., Doherty, P. C. & Lehner, P. J. 2000 Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. *Proc. Natl Acad. Sci. USA* **97**, 8455–8460.
- Stewart, J. P., Usherwood, E. J., Ross, A., Dyson, H. & Nash, T. 1998 Lung epithelial cells are a major site of murine gamma-herpesvirus persistence. *J. Exp. Med.* **187**, 1941–1951.
- Stewart, J. P., Micali, N., Usherwood, E. J., Bonina, L. & Nash, A. A. 1999 Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. *Vaccine* **17**, 152–157.
- Sunil-Chandra, N. P., Efstathiou, S. & Nash, A. A. 1992 Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes *in vivo*. *J. Gen. Virol.* **73**, 3275–3279.
- Sunil-Chandra, N. P., Arno, J., Fazakerley, J. & Nash, A. A. 1994 Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68. *Am. J. Pathol.* **145**, 818–826.
- Thomson, S. A. (and 12 others) 1996 Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. *J. Immunol.* **157**, 822–826.
- Thomson, S. A., Sherritt, M. A., Medveczky, J., Elliott, S. L., Moss, D. J., Fernando, G. J., Brown, L. E. & Suhrbier, A. 1998 Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. *J. Immunol.* **160**, 1717–1723.
- Thorley-Lawson, D. A., Miyashita, E. M. & Khan, G. 1996 Epstein-Barr virus and the B cell: that's all it takes. *Trends Microbiol.* **4**, 204–208.
- Topham, D. J. & Doherty, P. C. 1998a Clearance of an influenza A virus by CD4<sup>+</sup> T cells is inefficient in the absence of B cells. *J. Virol.* **72**, 882–885.
- Topham, D. J. & Doherty, P. C. 1998b Longitudinal analysis of the acute Sendai virus-specific CD4<sup>+</sup> T cell response and memory. *J. Immunol.* **161**, 4530–4535.
- Topham, D. J., Tripp, R. A., Sarawar, S. R., Sangster, M. Y. & Doherty, P. C. 1996 Immune CD4<sup>+</sup> T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. *J. Virol.* **70**, 1288–1291.
- Tripp, R. A., Hamilton-Easton, A. M., Cardin, R. D., Nguyen, P., Behm, F. G., Woodland, D. L., Doherty, P. C. & Blackman, M. A. 1997 Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? *J. Exp. Med.* **185**, 1641–1650.
- Usherwood, E. J., Ross, A. J., Allen, D. J. & Nash, A. A. 1996a Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. *J. Gen. Virol.* **77**, 627–630.
- Usherwood, E. J., Stewart, J. P., Robertson, K., Allen, D. J. & Nash, A. A. 1996b Absence of splenic latency in murine gammaherpesvirus 68-infected B cell-deficient mice. *J. Gen. Virol.* **77**, 2819–2825.
- Usherwood, E. J., Roy, D. J., Ward, K., Surman, S. L., Dutia, B. M., Blackman, M. A., Stewart, J. P. & Woodland, D. L. 2000 Control of  $\gamma$  herpesvirus latency by latent antigen-specific CD8<sup>+</sup> T cells. *J. Exp. Med.* **192**, 943–952.
- Van Berkel, V., Preiter, K., Virgin, H. W. & Speck, S. H. 1999 Identification and initial characterization of the murine gammaherpesvirus 68 gene M3, encoding an abundantly secreted protein. *J. Virol.* **73**, 4524–4529.
- Van Dyk, L. F., Hess, J. L., Katz, J. D., Jacoby, M., Speck, S. H. & Virgin, H. W. I. 1999 The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes. *J. Virol.* **73**, 5110–5122.
- Virgin, H. W. & Speck, S. H. 1999 Unraveling immunity to gamma-herpesviruses: a new model for understanding the role of immunity in chronic virus infection. *Curr. Opin. Immunol.* **11**, 371–379.
- Virgin, H. W., Latreille, P., Wamsley, P., Hallsworth, K., Weck, K. E., Dal Canto, A. J. & Speck, S. H. 1997 Complete sequence and genomic analysis of murine gammaherpesvirus 68. *J. Virol.* **71**, 5894–5904.
- Wang, G. H., Garvey, T. L. & Cohen, J. I. 1999 The murine gammaherpesvirus-68 M11 protein inhibits Fas- and TNF-induced apoptosis. *J. Gen. Virol.* **80**, 2737–2740.
- Weck, K. E., Barkon, M. L., Yoo, L. I., Speck, S. H. & Virgin, H. W. 1996 Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. *J. Virol.* **70**, 6775–6780.
- Weck, K. E., Dal Canto, A. J., Gould, J. D., O'Guin, A. K., Roth, K. A., Saffitz, J. E., Speck, S. H. & Virgin, H. W. 1997 Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. *Nat. Med.* **3**, 1346–1353.
- Wilson, A. D., Lovgren-Bengtsson, K., Villacres-Ericsson, M., Morein, B. & Morgan, A. J. 1999 The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. *Vaccine* **17**, 1282–1290.
- Yu, Z. Y., Manickan, E. & Rouse, B. T. 1996 Role of interferon-gamma in immunity to *Herpes simplex virus*. *J. Leukoc. Biol.* **60**, 528–532.
- Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M., Altman, J. D. & Ahmed, R. 1998 Viral immune evasion due to persistence of activated T cells without effector function. *J. Exp. Med.* **188**, 2205–2213.

